CYP19A1 and breast cancer: In our study, we analyzed treatment patterns only in subset of patients with BC treated with CDK4/6 inhibitors and found that CDK4/6 inhibitors were more commonly prescribed in combination with aromatase inhibitors and estrogen inhibitors, echoing findings from recent studies.